10-Q: Pluri Inc. Reports Increased Revenue but Widens Net Loss in Q1 2025

Pluri Inc. saw a significant increase in revenue driven by its CDMO and agtech businesses, but also experienced a widening net loss in the first quarter of fiscal year 2025.

Summary

• Pluri Inc. reported a net loss of $6.036 million for the quarter ended September 30, 2024, compared to a net loss of $5.098 million for the same period in 2023.
• The company's revenue increased to $326,000, up from $54,000 in the prior year, primarily due to its CDMO and agtech business segments.
• Research and development expenses, net of grants, decreased slightly to $2.889 million from $2.993 million year-over-year.
• General and administrative expenses rose to $2.509 million from $2.438 million, mainly due to increased salaries and share-based compensation.
• The company's cash and cash equivalents, including restricted cash, totaled $3.563 million as of September 30, 2024, down from $7.037 million as of June 30, 2024.
• Pluri's working capital surplus was $22.449 million, with a total equity deficit of $63,000, which includes a $5.220 million non-controlling interest in Ever After Foods.
• The company has an accumulated deficit of $426.354 million since its inception.
• Pluri believes its current resources are sufficient to meet its obligations for at least the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive revenue growth offset by a widening net loss and significant accumulated deficit. The company's reliance on external funding and the ongoing risks in Israel contribute to a cautious outlook.

Positives

• The company experienced a substantial increase in revenue due to the launch of new business verticals in CDMO and agtech.
• Pluri secured a $4.2 million contract with the NIAID, with $1.6 million received to date and an additional $2.2 million expected.
• The company has a working capital surplus of $22.449 million.
• Pluri has implemented a cost reduction and efficiency plan.
• The company regained compliance with Nasdaq's minimum shareholders' equity requirement.

Negatives

• The company's net loss widened to $6.036 million for the quarter.
• Pluri has an accumulated deficit of $426.354 million.
• Cash and cash equivalents decreased to $3.563 million.
• The company's total equity is in deficit at -$63,000.
• Other financial expenses increased significantly due to exchange rate differences related to the EIB loan.

Risks

• The company's operations are subject to substantial risks, including the ongoing armed conflict in Israel, which could disrupt operations.
• Pluri may need to obtain additional liquidity resources to support commercialization and R&D activities.
• The company has a significant accumulated deficit and may not generate significant revenue in the next twelve months.
• The company is subject to risks related to the EIB loan, including royalty payments and limitations on the use of proceeds.
• The company's financial results could be adversely affected if the IIA no longer provides grants.

Future Outlook

Pluri expects to generate revenue from CDMO services, collaborations, and licenses, but does not anticipate significant product sales in the next twelve months. The company may need to obtain additional liquidity resources to support commercialization and R&D activities. Pluri believes it has sufficient cash to fund operations for at least the next twelve months.

Management Comments

• The company's management believes that its current resources, together with its existing operating plan, are sufficient to meet its obligations for at least twelve months.
• Management is continually looking for sources of funding, including collaborations, grants, and sales of common shares.

Industry Context

Pluri's expansion into CDMO and agtech aligns with the growing demand for cell-based manufacturing services and sustainable agricultural solutions. The company's focus on regenerative medicine and immunotherapy also positions it in a rapidly evolving sector with significant growth potential. The company is competing with other biotech companies in the cell therapy space, and the success of its new business verticals will be critical for its future growth.

Comparison to Industry Standards

• Pluri's revenue growth, while significant on a percentage basis, is still relatively low compared to established CDMO companies such as Lonza or Catalent, which generate hundreds of millions of dollars in revenue per quarter.
• The company's net loss is substantial, and its accumulated deficit is a concern, especially when compared to more mature biotech companies with established revenue streams.
• Pluri's cash position is relatively weak compared to companies with similar market capitalizations, which typically have tens or hundreds of millions of dollars in cash reserves.
• The company's reliance on grants and non-dilutive funding is common in the early stages of biotech development, but it needs to demonstrate the ability to generate sustainable revenue to achieve long-term success.
• Pluri's focus on innovative technologies like MAIT cells and 3D cell expansion positions it well in the long term, but it needs to demonstrate clinical and commercial success to compete with established players in the cell therapy market.

Stakeholder Impact

• Shareholders may be concerned about the widening net loss and the company's accumulated deficit.
• Employees may be affected by the ongoing conflict in Israel and potential disruptions to operations.
• Customers of the CDMO business may benefit from the company's cell manufacturing capabilities.
• Partners and collaborators may be impacted by the company's financial performance and operational risks.

Next Steps

• The company will continue to develop its cell-based technologies and expand its CDMO and agtech businesses.
• Pluri will seek additional funding through collaborations, grants, and sales of equity securities.
• The company will continue to monitor the situation in Israel and its potential impact on operations.
• Pluri will continue to advance its clinical and pre-clinical studies.

Key Dates

Keywords

CDMO, agtech, cell therapy, regenerative medicine, immunotherapy, MAIT cells, PLX cells, biotechnology, financial results, EIB loan, NIAID, research and development, revenue, net loss